Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Implant for DME
Description
On this episode of ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum, Dr. Timothy Murray welcomes David S. Boyer, MD, of Retina Vitreous Associates Medical Group (LA Retina) Los Angeles, CA, to discuss real-world outcomes for use of the 0.19 mg fluocinolone implant in treating diabetic macular edema in 148 eyes, documenting stable VA, decreased central subfield thickness, and a reduced need for intravitreal anti-VEGF. Tune in for a discussion on why the 0.19 mg fluocinolone acetonide intravitreal implant provided long-term stabilization of VA and macular anatomy in patients with DME, despite a significant reduction in treatment frequency.
For more information, visit www.ASRS.org/JVRDForum.
Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief for JVRD as he discusses cutting-edge developments featured in JVRD with the lead authors who share clinical pearls and explore their significance for advancing patient care.
United States
